<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158262">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153593</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-EVI-2011-138</org_study_id>
    <secondary_id>EC11-340</secondary_id>
    <secondary_id>2011-006276-40</secondary_id>
    <nct_id>NCT02153593</nct_id>
  </id_info>
  <brief_title>Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial</brief_title>
  <acronym>TRANEXTUM</acronym>
  <official_title>Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Massive bone tumour resection is often associated with important postoperative bleeding.
      This may determine systemic (anaemia), as well as local complications (wound healing,
      seroma, haematoma).

      The objective of this study is to determine whether the use of topical tranexamic acid or
      topical Evicel® will reduce the perioperative bleeding comparing it with  usual haemostasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total blood loss (mL) in the postoperative period</measure>
    <time_frame>The first postoperative 48h</time_frame>
    <safety_issue>No</safety_issue>
    <description>The blood loss will be collected by the drainage system and quantified in mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring blood transfusion</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of blood transfused</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound infection</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound dehiscence</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with reoperation for wound complications</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep venous thrombosis</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with seroma</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain related with the surgery</measure>
    <time_frame>The first postoperative week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral local relapse rate</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral systemic dissemination rate</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in which chemotherapy is delayed for wound complications</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in which radiotherapy is delayed for wound complications.</measure>
    <time_frame>The first postoperative month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Blood Loss</condition>
  <condition>Bone Tumour</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid, 1g intra-articular before closing the surgery wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual hemostasia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrocauterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1g intra-articular before closing the wound surgery</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>5mL intra-articular before closing the wound surgery</description>
    <arm_group_label>Fibrin glue</arm_group_label>
    <other_name>Evicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrocauterization</intervention_name>
    <description>Coagulation blood from vessels by means of a electrocautery</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_label>Usual hemostasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Osseous tumor (primary or metastatic, benign or malignant) located in extremities,
             shoulder girdle or pelvis.

          -  Massive or bloc tumour resection.

          -  Patient's consent to participate

        Exclusion Criteria:

          -  Known allergy to ATX

          -  Allergy or known hypersensitivity to bovine proteins (aprotinin)

          -  Liposarcomas low grade

          -  History of thromboembolic disease or prothrombotic conditions:

               -  cerebral vascular accident

               -  ischemic heart disease

               -  deep and / or superficial vein thrombosis

               -  pulmonary embolism

               -  peripheral arterial vasculopathy

               -  thrombogenic arrhythmias (eg: ACxFA)

               -  patients with cardiovascular stents

               -  prothrombotic alterations in coagulation

               -  Treatment with contraceptive drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Peiró, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MJ Martinez-Zapata, MD, PhD</last_name>
    <phone>34 93 553 78 08</phone>
    <email>mmartinezz@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo,</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Areizaga, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>L Areizaga, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Alacalà, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>R Alcalà, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Peiró, MD</last_name>
    </contact>
    <investigator>
      <last_name>A Peiró, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical trial</keyword>
  <keyword>Randomized</keyword>
  <keyword>Fibrin glue</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Blood loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
